Hartung Josephine, Müller Christine, Calkhoven Cornelis F
European Research Institute for the Biology of Ageing (ERIBA), University Medical Center Groningen, University of Groningen, 9700 AD Groningen, The Netherlands.
European Research Institute for the Biology of Ageing (ERIBA), University Medical Center Groningen, University of Groningen, 9700 AD Groningen, The Netherlands.
Trends Mol Med. 2025 May;31(5):452-465. doi: 10.1016/j.molmed.2024.10.009. Epub 2024 Nov 1.
The tuberous sclerosis complex (TSC1/TSC2/TBC1D7) primarily functions to inhibit the mechanistic target of rapamycin complex 1 (mTORC1), a crucial regulator of cell growth. Mutations in TSC1 or TSC2 cause tuberous sclerosis complex (TSC), a rare autosomal dominant genetic disorder marked by benign tumors in multiple organs that rarely progress to malignancy. Traditionally, TSC proteins are considered tumor suppressive due to their inhibition of mTORC1 and other mechanisms. However, more recent studies have shown that TSC proteins can also promote tumorigenesis in certain cancer types. In this review, we explore the composition and function of the TSC protein complex, the roles of its individual components in cancer biology, and potential future therapeutic targeting strategies.
结节性硬化症复合物（TSC1/TSC2/TBC1D7）主要功能是抑制雷帕霉素靶蛋白复合物1（mTORC1），这是细胞生长的关键调节因子。TSC1或TSC2的突变会导致结节性硬化症（TSC），这是一种罕见的常染色体显性遗传病，其特征是多个器官出现良性肿瘤，很少发展为恶性肿瘤。传统上，由于TSC蛋白对mTORC1的抑制作用及其他机制，它们被认为具有肿瘤抑制作用。然而，最近的研究表明，TSC蛋白在某些癌症类型中也可促进肿瘤发生。在本综述中，我们探讨了TSC蛋白复合物的组成和功能、其各个组分在癌症生物学中的作用以及潜在的未来治疗靶向策略。
